

COVID-19 and Kidney Transplantation: Clinical Outcomes, Management, and Challenges

Guest Editor:

Dr. Didier Ducloux

1. CHU Besançon, Department of Nephrology, Dialysis and Renal Transplantation, Federation Hospitalo-Universitaire INCREASE, 25000 Besançon, France
2. UMR RIGHT 1098, INSERM-EFS-UFC, 1 Bd Fleming, 25000 Besançon, France

Deadline for manuscript submissions:


closed (20 July 2022)

Message from the Guest Editor

Several studies have reported that kidney transplant recipients (KTR) are at increased risk of severe COVID-19 infection. Furthermore, the efficacy of the vaccine is severely reduced in these patients. Therefore, individualized prevention strategies are essential for KTR. Adaptation of the vaccine scheme is recommended in these patients, including the use of an early third dose and of a fourth dose in vaccine responders. However, the net effect of each immunosuppressant on vaccine response may vary, and optimization of the immunosuppressive regimen to improve immunization is practicable. Minimization of immunosuppression and effects of conventional treatment of severe COVID infection are also crucial questions in patients with COVID-19 infection. Finally, a global and integrative approach to COVID-19 infection prevention is required.

This special issue aims to highlight current knowledge on COVID-19 in KTR. Different studies include personalized prevention, clinical outcomes, medical care, and future challenges. Indeed, this pandemic raises in an acute fashion the question of vaccine protocols and how to approach them in immunocompromised patients.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)